Abstract-In recent years, researchers have evaluated the clinical efficacy and safety of Leflunomide (LEF) and other medications for the treatment of rheumatoid arthritis (RA
I. INTRODUCTION
In recent years, researchers have evaluated the clinical efficacy and safety of LEF (figure 1) and other medications for the treatment of rheumatoid artitis (RA).
In their results, they announced that, in the treatment of RA with these combinations, it presented the characteristics of remarkably lowering the levels of laboratory indices. [1] [2] [3] In other studies, it was concluded that a weekly dose of 50 mg of LEF showed similar benefits to the 10 mg daily dose of the same medication in the treatment of moderate to moderate rheumatoid arthritis. [4] We also compared the short-term efficacy of LEF and Methotrexate in the treatment of RA and did not find significant statistical differences. [5] They evaluated the clinical efficacy and safety of LEF as a new immunosuppressive medicine in lupus nephritis through a meta-analysis. LEF is a promising therapy for the treatment of lupus nephritis, mainly because of the efficacy and favorable safety profile determined by a meta-analysis. [6] A proportion of patients who achieved significant clinical benefit after an adequate trial of LEF was evaluated. A significant proportion of patients, most of whom had previously failed treatment with methotrexate, were able to respond to the disease with LEF with a low risk of adverse effects, suggesting that treatment with LEF may be a reasonable and cost-effective strategy in the face of https://dx.doi.org/10.22161/ijaems. The initiation and monitoring practices of rheumatologists in Australia using LEF were also evaluated. The choice of the initial dose of LEF among the Australian rheumatologists who responded varied considerably.
[10]
Other researchers studied the profile of side effects and survival characteristics of LEF used in a regional population of patients in New Zealand (NZ). They concluded that their studies suggest a better profile of side effects and better survival of the drug for LEF than suggested by previous studies with a survival comparable to that of methotrexate. The quantum calculations we carry out with the hyperchem software. These calculations were made in other articles already published by us. [11] [12] [13] [14] [15] III. RESULTS AND DISCUSSIONS We characterize human glycogen with the software model 6000. [18] Information on the sequencing of this protein was taken from the NCBI database. In Figure 2 the graph is presented. You can see that Gly is the most abundant amino acid of all its structural composition; while Trp is the amino acid with fewer units. In Table 1 it can be seen that the lowest value of ETC corresponds to the LEF-O2 interaction; This means that the LEF is easily oxidized. It can also be seen that the LEF-H2O interaction is not as deep in the quantum well; this indicates that the LEF is not very soluble in water. Table 2 shows the calculations of two new concepts. The quantum molecular impedance is relative to water (QMIRW) and the quantum molecular conductan ce relative to water (QMCRW). With these two concepts, the reader will better understand the concept of ETC. We can observe in this table 2 that the LEF-O2 interaction has almost half the value of the valence electron jump impedance of LEF towards O2 than the jump of H2O to another molecule of H2O. With the conductance, the opposite happens. indicated with one *. Within these five interactions are the interactions of the LEF with His and Arg in oxidizing form. Therefore, these LEF interactions are the most dangerous because they are oxidants. Table 4 , we summarize the most significant interactions for LEF anchors in collagen amino acids. 
II. MATERIALS AN METHODS

IV. CONCLUSIONS In
